A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Clinical trial NCT06834360 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06834360
- Sponsor
- Sanofi
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-06
- Primary completion
- 2026-11-06
- Enrollment
- 216
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.